Russell Frank Company’s Corcept Therapeutics CORT Stock Holding History

Russell Frank Company’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$621K	Buy	132,596 +23,308	+21%	+$90.8K	﹤0.01%	2379
2015 Q4	$562K	Sell	109,288 -3,360	-3%	-$15.2K	﹤0.01%	2457
2015 Q3	$424K	Sell	112,648 -82,515	-42%	-$419K	﹤0.01%	2522
2015 Q2	$1.17M	Hold	195,163	–	–	﹤0.01%	2228
2015 Q1	$1.09M	Buy	+195,163	New	+$707K	﹤0.01%	2094
2013 Q4	–	Sell	-290	Closed	–	–	2847
2013 Q3	$0	Buy	290 +11	+4%	+$19	﹤0.01%	3451
2013 Q2	$0	Buy	+279	New	+$502	﹤0.01%	3354

Other funds holding CORT

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BGIM

Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return

Russell Frank Company's CORT Position: Q1 2016 in Review

Russell Frank Company increased its Corcept Therapeutics (CORT) stake by 21% in Q1 2016, buying an estimated $90.8K and bringing the position to 132,596 shares worth $621K. The position accounts for ﹤0.01% of the portfolio, ranked #2379.

Russell Frank Company first reported a position in CORT in Q2 2013 and has held it in 7 quarters since. The position peaked at $1.17M in Q2 2015. 96 funds tracked by Wall St. Rank hold CORT as of Q1 2016.

Russell Frank Company held 132,596 shares of Corcept Therapeutics worth $621K as of Q1 2016.
Russell Frank Company bought 23,308 Corcept Therapeutics shares in Q1 2016, an estimated $90.8K.
Corcept Therapeutics made up ﹤0.01% of Russell Frank Company's portfolio in Q1 2016, its #2379 holding.
Russell Frank Company first reported a position in Corcept Therapeutics in Q2 2013 and has held it in 7 quarters since.
Russell Frank Company's Corcept Therapeutics position peaked at $1.17M in Q2 2015.
96 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.